Top

Published in:

Open Access 01-12-2018 | Research

An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France

Authors: Patrick Blin, Pascal Demoly, Martine Drouet, Bruno Falissard, Séverine Lignot-Maleyran, Hélène Maizi, Simon Lorrain, Régis Lassalle, Cécile Droz-Perroteau, Nicholas Moore, Mathieu Molimard

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2018

Abstract

Background

Allergic rhinitis affects around one quarter of the Western European population. Prophylactic allergen immunotherapy may be useful to reduce the risk of acute symptomatic attacks (hayfever). A five-grass pollen extract sublingual immunotherapy (5GPE-SLIT) has been developed for the treatment of allergic rhinitis to grass pollen. The objective of this study was to describe real-world treatment patterns with 5GPE-SLIT in France with respect to the prescribing information.

Methods

This prospective cohort study was conducted by 90 community and hospital allergists. Adults and children (> 5 years old) starting a first treatment with 5GPE-SLIT prior to the 2015 pollen season were eligible. Data was collected at the inclusion visit and at the end of the pollen season. The primary outcome variable was compatibility of 5GPE-SLIT prescription with the prescribing information. This was determined with respect to four variables: (1) interval between 5GPE-SLIT initiation and onset of the pollen season ≥ 3 months, (2) age of patient ≥ 5 years, (3) intermittent symptoms or mild symptom severity (4) confirmatory diagnostic test. At study end, symptoms reported during the pollen season and any modifications to treatment or adverse events were documented.

Results

280 adults and 203 children were enrolled. The prescribing information was respected for 82.5% of adults and 86.7% of children. A skin test was performed for all patients. 5GPE-SLIT was started 3–5 months before the pollen season for 85.3%. Treatment was discontinued before the start of the pollen season in 11.0% of patients overall, generally because of an adverse event (78.8% of discontinuations). The mean duration of treatment was 5.2 months in adults and 5.6 months in children. At the end of follow-up, symptoms during the pollen season were intermittent for 75.0% of adults and 85.7% of children, and severity was mild for 61.8 and 66.0% respectively. During 5GPE-SLIT, the following symptoms reported during the previous year were not reported again in > 50% of patients: nasal congestion, rhinorrhoea, repeated sneezing, conjunctivitis and nasal pruritus.

Conclusions

5GPE-SLIT use was generally consistent with prescribing recommendations and was associated with an improvement of AR severity, with resolution of the principal AR symptoms in around half the patients treated.

Trial registration EUPAS9358. Registered 13 May 2015. Not prospectively registered. http://www.encepp.eu/encepp/viewResource.htm?id=16229

Available only for authorised users

Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372:456–63. https://doi.org/10.1056/NEJMcp1412282.CrossRefPubMedPubMedCentral

Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x.CrossRefPubMed

Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758–64. https://doi.org/10.1183/09031936.04.00013904.CrossRefPubMed

Klossek JM, Annesi-Maesano I, Pribil C, Didier A. INSTANT: national survey of allergic rhinitis in a French adult population based-sample. Presse Med. 2009;38:1220–9. https://doi.org/10.1016/j.lpm.2009.05.012.CrossRefPubMed

Bhattacharyya N. Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy. 2012;26:120–2. https://doi.org/10.2500/ajra.2012.26.3752.CrossRefPubMedPubMedCentral

Majani G, Baiardini I, Giardini A, et al. Health-related quality of life assessment in young adults with seasonal allergic rhinitis. Allergy. 2001;56:313–7.CrossRefPubMed

Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am. 2016;36:235–48. https://doi.org/10.1016/j.iac.2015.12.002.CrossRefPubMed

Cingi C, Gevaert P, Mosges R, et al. Multi-morbidities of allergic rhinitis in adults: European academy of allergy and clinical immunology task force report. Clin Transl Allergy. 2017;7:17. https://doi.org/10.1186/s13601-017-0153-z.CrossRefPubMedPubMedCentral

D’Amato G, Spieksma FT, Liccardi G, et al. Pollen-related allergy in Europe. Allergy. 1998;53:567–78.CrossRefPubMed

10.

Panzani RC, Mercier P, Delord Y, et al. Prevalence of patent and latent atopy among a general normal adult population in the south east of France by RAST investigation and correlation with circulating total IgE levels. Allergol Immunopathol (Madr). 1993;21:211–9.PubMed

11.

Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17:1–322. https://doi.org/10.3310/hta17270.CrossRef

12.

Calderon MA, Cox L, Casale TB, et al. The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. Allergy Asthma Clin Immunol. 2015;11:17. https://doi.org/10.1186/s13223-015-0083-z.CrossRefPubMedPubMedCentral

13.

Passalacqua G, Canonica GW, Bagnasco D. Benefit of SLIT and SCIT for allergic rhinitis and asthma. Curr Allergy Asthma Rep. 2016;16:88. https://doi.org/10.1007/s11882-016-0666-x.CrossRefPubMed

14.

Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(1327–1334):e1321. https://doi.org/10.1016/j.jaci.2012.08.032.CrossRef

15.

Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–45. https://doi.org/10.1016/j.jaci.2007.07.046.CrossRefPubMed

16.

Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128:559–66. https://doi.org/10.1016/j.jaci.2011.06.022.CrossRefPubMed

17.

Franzke N, Schafer I, Jost K, et al. A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy. 2011;66:665–70. https://doi.org/10.1111/j.1398-9995.2010.02515.x.CrossRefPubMed

18.

Demoly P, Aubier M, de Blay F, Wessel F, Clerson P, Maigret P. Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index—the benefica study. Allergy Asthma Clin Immunol. 2015;11:8. https://doi.org/10.1186/s13223-015-0073-1.CrossRefPubMedPubMedCentral

19.

Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147–334.CrossRefPubMed

20.

World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology: guidelines for ATC classification and DDD assignment. Oslo: WHO-CCDSM; 2017.

21.

Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A, Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009;64:166–71. https://doi.org/10.1111/j.1398-9995.2008.01767.x.CrossRefPubMed

22.

Didier A, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opin Drug Saf. 2015;14:777–88. https://doi.org/10.1517/14740338.2015.1017468.CrossRefPubMed

23.

Shah-Hosseini K, Mioc K, Hadler M, Karagiannis E, Mosges R. Optimum treatment strategies for polyallergic patients—analysis of a large observational trial. Curr Med Res Opin. 2015;31:2249–59. https://doi.org/10.1185/03007995.2015.1094653.CrossRefPubMed

24.

Antolin D, Valbuena T, Valls A, Garrido S, Blanco C, Garcia MA. One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts. Findings of the SMILE study. In: European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. Milan; 2013.

Title: An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France
Authors: Patrick Blin
Pascal Demoly
Martine Drouet
Bruno Falissard
Séverine Lignot-Maleyran
Hélène Maizi
Simon Lorrain
Régis Lassalle
Cécile Droz-Perroteau
Nicholas Moore
Mathieu Molimard
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2018
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/s13223-018-0262-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Frequency of CD4+ and CD8+ T cells in Iranian chronic rhinosinusitis patients

The law of food allergy and accommodation in Canadian schools

Histone modifications and their role in epigenetics of atopy and allergic diseases

Correction to: Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction

Component resolved analysis of ash pollen allergy in Bavaria

Sweet syndrome: a rare feature of ANCA-associated vasculitis or unusual consequence of azathioprine-induced treatment